இயக்குனர் ப்ரோக்ர்யாம் மேலாண்மை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from இயக்குனர் ப்ரோக்ர்யாம் மேலாண்மை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In இயக்குனர் ப்ரோக்ர்யாம் மேலாண்மை Today - Breaking & Trending Today

Intravacc announces positive preclinical data for its SARS- CoV-2 nose spray vaccine


Intravacc announces positive preclinical data for its SARS- CoV-2 nose spray vaccine
Intranasal administration of OMV-Spike protected against challenge with SARS-CoV-2
Intranasal vaccine administration has significant advantages over injectables
OMV technology is a powerful vaccine platform for future pandemics
 
Bilthoven, The Netherlands, 7 April 2021 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has obtained positive preclinical results for its SARS-CoV-2 Outer Membrane Vesicle (OMV) based recombinant Spike protein (rSp) candidate nose spray vaccine.
For the preclinical study four groups of mice and four groups of hamsters received two intranasal immunizations on day one and day 21. One group of mice and hamsters received a vaccine based on OMV’s mixed with rSp (CovOMV) and the other a vaccine based on OMV’s coupled to rSp based on Intravacc’s proprietary OMV click ....

Dinja Oosterhoff , Program Management At Intravacc , Membrane Vesicle , Director Program Management , இயக்குனர் ப்ரோக்ர்யாம் மேலாண்மை ,

Intravacc announces positive preclinical data for its SARS-CoV-2 nose spray vaccine


Share this article
Share this article
BILTHOVEN, Netherlands, April 7, 2021 /PRNewswire/  Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has obtained positive preclinical results for its SARS-CoV-2 Outer Membrane Vesicle (OMV) based recombinant Spike protein (rSp) candidate nose spray vaccine.
For the preclinical study four groups of mice and four groups of hamsters received two intranasal immunizations on day one and day 21. One group of mice and hamsters received a vaccine based on OMV s mixed with rSp (CovOMV) and the other a vaccine based on OMV s coupled to rSp based on Intravacc s proprietary OMV click technology (CovOMVclick). Control animals received respectively only OMV s or only rSp. On day 35 the mice blood samples were tested for virus neutralizing antibodies. The hamsters were challenged with SARS-CoV-2 on day 42 after blood collection. Over a period of seven days after chal ....

Noord Holland , Mirjam Hartman , Dinja Oosterhoff , Program Management At Intravacc , Melinda Gates Foundation , Lifespring Life Sciences Communication , Membrane Vesicle , Director Program Management , Jan Groen , Utrecht Science Park Bilthoven , Spring Life Sciences Communication , நூற்த் ஹாலண்ட் , மெலிண்டா வாயில்கள் அடித்தளம் , ஆயுட்காலம் வாழ்க்கை அறிவியல் தொடர்பு , இயக்குனர் ப்ரோக்ர்யாம் மேலாண்மை , ஜான் இடுப்பு , வசந்த வாழ்க்கை அறிவியல் தொடர்பு ,